Oric Pharmaceuticals Elects Directors at Annual Meeting

An announcement from Oric Pharmaceuticals ( (ORIC) ) is now available.

On June 11, 2025, Oric Pharmaceuticals held its annual stockholders meeting, where 82.02% of the outstanding common stock was represented. During the meeting, two Class II directors, Steven L. Hoerter and Angie You, Ph.D., were elected to serve until the 2028 annual meeting, and the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

The most recent analyst rating on (ORIC) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.

Spark’s Take on ORIC Stock

According to Spark, TipRanks’ AI Analyst, ORIC is a Neutral.

Oric Pharmaceuticals’ overall score reflects the significant risks associated with its current financial performance, characterized by ongoing losses and no revenue generation. Despite a strong balance sheet with substantial cash reserves, the company’s stock is under pressure due to bearish technical indicators and uncertain valuation metrics. The expansion of the equity incentive plan is a strategic positive but does not offset the immediate financial challenges.

To see Spark’s full report on ORIC stock, click here.

More about Oric Pharmaceuticals

Oric Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing innovative therapies for cancer treatment.

Average Trading Volume: 1,166,320

Technical Sentiment Signal: Buy

Current Market Cap: $667.5M

See more data about ORIC stock on TipRanks’ Stock Analysis page.